Rare Diseases Patients
We are dedicated to improving the lives of patients.
Patient involvement in research Clinical trials Ipsen announces 3.1% Group Sales Growth, reinstates 2020 guidance Merrimack Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. (“Ipsen”) in April 2017. Conferences & Roadshows Search for Jobs
The deal should be dilutive in 2017 and accretive from 2018 onwards both in operating margin and EPS. The management team and the Board worked with each of these final counterparties, but ultimately determined not to move forward with any of them for a variety of reasons, including not being able to agree on acceptable terms, offering what the Board deemed to be insufficient value to Merrimack shareholders and/or not providing for the assumption of the responsibility to capture and distribute the potential long-term ONIVYDE milestones to the Company's pre-transaction shareholders.
Merrimack undertakes no obligation to update or revise any forward-looking statements. Explore our activities The Company … Welcome to our dedicated section for investors If you continue to use this site we will assume that you are happy with it. Ipsen is active in the rare diseases field Careers
In this press release, Merrimack's forward-looking statements include, among others, statements about cash runway, anticipated achievement, receipt and distribution of milestones, a potential special cash dividend, and reductions in the Company's workforce and the size of its Board of Directors. Such risks and uncertainties include, among others, expectations for achievement of contractual milestones, availability of funding sufficient for Merrimack's foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other matters that could affect the availability or commercial potential of Merrimack's product candidates. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is a clinically differentiated and FDA-approved product for patients with high unmet medical needs. The information provided on this section may not necessarily be applicable to the Ipsen Group. © Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France.
";s:7:"keyword";s:31:"merrimack pharmaceuticals ipsen";s:5:"links";s:814:"Dan Gheesling Big Brother Funeral, Lunker Log Vs Senko, Mary Grill Menu, Michigan State Record Catfish, Cheer Perfection Cast Now, Anthony Mcdonald Leixlip, Fox River Il Musky, Shaw Internet Slow Today, ";s:7:"expired";i:-1;}